Pictet Asset Management Ltd. Has $29.78 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Pictet Asset Management Ltd. cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 454,896 shares of the biopharmaceutical company’s stock after selling 108,875 shares during the period. Pictet Asset Management Ltd.’s holdings in Alnylam Pharmaceuticals were worth $29,778,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of ALNY. TD Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 36.8% in the second quarter. TD Asset Management Inc. now owns 129,918 shares of the biopharmaceutical company’s stock valued at $10,362,000 after buying an additional 34,918 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Alnylam Pharmaceuticals by 25.4% in the second quarter. Candriam Luxembourg S.C.A. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $6,700,000 after buying an additional 17,000 shares in the last quarter. World Asset Management Inc bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $277,000. CIBC Asset Management Inc bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $221,000. Finally, Hemenway Trust Co LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $235,000. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 75.94 on Friday. The company’s 50-day moving average price is $81.11 and its 200 day moving average price is $61.63. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $86.92. The company’s market cap is $6.55 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The firm had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 48.01% and a negative net margin of 670.81%. The company’s revenue was up 82.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.21) EPS for the current year.
Several equities research analysts have weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $56.00 target price (up from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Chardan Capital reaffirmed a “buy” rating and issued a $124.00 target price (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Thursday. Barclays PLC increased their target price on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, BidaskClub raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $81.74.
In other news, major shareholder Sanofi bought 297,501 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average price of $71.87 per share, for a total transaction of $21,381,396.87. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Akshay Vaishnaw sold 43,750 shares of the business’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $65.00, for a total value of $2,843,750.00. Following the sale, the senior vice president now owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is currently owned by corporate insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.